RxDoctor Payments Data

Chanelle Perry

Family · Youngstown, OHNPI 1487058913

Payments from drug & device makers

$2,808in general payments, 2019–2025

Across 140 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$260
  • Biohaven Pharmaceuticals, Inc.$137
  • Biogen$137
  • Abbott$136
  • Novo Nordisk$123
  • plus $702 from 17 others

What the payments were for

  • Food & beverage$2,808100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,808 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$27,095
Medicare patients
157
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tetrabenazine13$93,436
Nurtec OdtRimegepant Sulfate15$24,365
BriviactBrivaracetam11$18,336
Emgality SyringeGalcanezumab-Gnlm11$9,380
Lacosamide33$8,150
Levetiracetam133$4,197
Donepezil Hcl83$3,687
Memantine Hcl119$3,598
Oxcarbazepine20$2,674
Dimethyl Fumarate11$2,053
Primidone117$1,945
Gabapentin47$1,222
RivastigmineRivastigmine Tartrate20$1,150
Topiramate56$912
Amitriptyline Hcl32$729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$13$24,36515 claims
UCB, Inc.Briviact$91$18,33611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →